Baseline clinical characteristics of patients with WM before the initial SARS-CoV-2 vaccination (cohort 2)
| Patient characteristic . | All patients (n = 48) . |
|---|---|
| Age, y | |
| Median (range) | 67 (49-81) |
| >75, n (%) | 5 (10) |
| Male sex, n (%) | 28 (58) |
| Race, n (%) | |
| White | 46 (96) |
| Non-White | 2 (4) |
| COVID-19 vaccine, n (%) | |
| BNT162b2 | 28 (58) |
| mRNA-1273 | 17 (35) |
| JNJ-78436735 | 3 (6) |
| MYD88 mutation, n (%) | |
| Mutated | 35 (73) |
| WT | 8 (17) |
| Unknown | 5 (10) |
| CXCR4 mutation, n (%) | |
| Mutated | 11 (23) |
| WT | 12 (25) |
| Unknown | 25 (52) |
| Asymptomatic WM, n (%) | 8 (17) |
| Treatment status, n (%) | |
| Treatment naïve | 12 (25) |
| Previously treated | 36 (75) |
| Median no. of previous treatment lines (range) | 1 (1-4) |
| Current treatment regimens,∗ n (%) | |
| BTKi | 21 (58) |
| Rituximab | 8 (17) |
| Venetoclax | 4 (8) |
| Bendamustine | 2 (4) |
| Proteasome inhibitor | 2 (4) |
| Corticosteroid | 2 (4) |
| Fludarabine | 1 (2) |
| Median serum immunoglobulin level (IQR), mg/dL | |
| IgM | 837 (39-5835) |
| IgG | 598 (121-1825) |
| IgA | 42 (5-285) |
| Hypogammaglobulinemia (IgG <400 mg/dL), n (%) | 34 (71) |
| IV immunoglobulin within 90 days, n (%) | 5 (10) |
| Comorbidities, n (%) | |
| Pulmonary disease | 7 (15) |
| Chronic kidney disease | 6 (13) |
| Diabetes | 1 (2) |
| Hypertension | 15 (31) |
| Cardiovascular disease | 7 (15) |
| Obesity (BMI >30 kg/m2) | 5 (10) |
| Current tobacco use | 6 (13) |
| Patient characteristic . | All patients (n = 48) . |
|---|---|
| Age, y | |
| Median (range) | 67 (49-81) |
| >75, n (%) | 5 (10) |
| Male sex, n (%) | 28 (58) |
| Race, n (%) | |
| White | 46 (96) |
| Non-White | 2 (4) |
| COVID-19 vaccine, n (%) | |
| BNT162b2 | 28 (58) |
| mRNA-1273 | 17 (35) |
| JNJ-78436735 | 3 (6) |
| MYD88 mutation, n (%) | |
| Mutated | 35 (73) |
| WT | 8 (17) |
| Unknown | 5 (10) |
| CXCR4 mutation, n (%) | |
| Mutated | 11 (23) |
| WT | 12 (25) |
| Unknown | 25 (52) |
| Asymptomatic WM, n (%) | 8 (17) |
| Treatment status, n (%) | |
| Treatment naïve | 12 (25) |
| Previously treated | 36 (75) |
| Median no. of previous treatment lines (range) | 1 (1-4) |
| Current treatment regimens,∗ n (%) | |
| BTKi | 21 (58) |
| Rituximab | 8 (17) |
| Venetoclax | 4 (8) |
| Bendamustine | 2 (4) |
| Proteasome inhibitor | 2 (4) |
| Corticosteroid | 2 (4) |
| Fludarabine | 1 (2) |
| Median serum immunoglobulin level (IQR), mg/dL | |
| IgM | 837 (39-5835) |
| IgG | 598 (121-1825) |
| IgA | 42 (5-285) |
| Hypogammaglobulinemia (IgG <400 mg/dL), n (%) | 34 (71) |
| IV immunoglobulin within 90 days, n (%) | 5 (10) |
| Comorbidities, n (%) | |
| Pulmonary disease | 7 (15) |
| Chronic kidney disease | 6 (13) |
| Diabetes | 1 (2) |
| Hypertension | 15 (31) |
| Cardiovascular disease | 7 (15) |
| Obesity (BMI >30 kg/m2) | 5 (10) |
| Current tobacco use | 6 (13) |
IQR, interquartile range.
Among patients who were receiving active treatment at the time of vaccination (n = 36).